These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2018005)

  • 1. Concentration-effect relations of 5-hydroxypropafenone in normal subjects.
    Haefeli WE; Vozeh S; Ha HR; Taeschner W; Follath F
    Am J Cardiol; 1991 May; 67(11):1022-6. PubMed ID: 2018005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog.
    Boucher M; Chassaing C; Hamel JD; Poirier JM
    Eur J Pharmacol; 1996 Nov; 315(2):171-7. PubMed ID: 8960881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG; Kirsten EB; Brewington J
    Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
    Arias C; González T; Moreno I; Caballero R; Delpón E; Tamargo J; Valenzuela C
    Cardiovasc Res; 2003 Mar; 57(3):660-9. PubMed ID: 12618228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response.
    Ito S; Gow R; Verjee Z; Giesbrecht E; Dodo H; Freedom R; Tonn GR; Axelson JE; Zalzstein E; Rosenberg HC; Koren G
    J Clin Pharmacol; 1998 Jun; 38(6):496-501. PubMed ID: 9650538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ECG changes and plasma concentrations of propafenone and its metabolites in a case of severe poisoning.
    Fonck K; Haenebalcke C; Hemeryck A; Belpaire F; Jordaens L; Calle P; Buylaert W
    J Toxicol Clin Toxicol; 1998; 36(3):247-51. PubMed ID: 9656983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.
    Bachmakov I; Rekersbrink S; Hofmann U; Eichelbaum M; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar; 371(3):195-201. PubMed ID: 15900513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.
    von Philipsborn G; Gries J; Hofmann HP; Kreiskott H; Kretzschmar R; Müller CD; Raschack M; Teschendorf HJ
    Arzneimittelforschung; 1984; 34(11):1489-97. PubMed ID: 6543124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propafenone shows class Ic and class II antiarrhythmic effects.
    Stoschitzky K; Stoschitzky G; Lercher P; Brussee H; Lamprecht G; Lindner W
    Europace; 2016 Apr; 18(4):568-71. PubMed ID: 26056191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective steady state disposition and action of propafenone in Chinese subjects.
    Li G; Gong PL; Qiu J; Zeng FD; Klotz U
    Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
    Funck-Brentano C; Kroemer HK; Pavlou H; Woosley RL; Roden DM
    Br J Clin Pharmacol; 1989 Apr; 27(4):435-44. PubMed ID: 2719900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E; Müller-Peltzer H; Hollmann M
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites.
    Rouini MR; Afshar M
    Therapie; 2017 Jun; 72(3):373-382. PubMed ID: 28087064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
    Jazwinska-Tarnawska E; Orzechowska-Juzwenko K; Niewinski P; Rzemislawska Z; Loboz-Grudzien K; Dmochowska-Perz M; Slawin J
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.
    Capucci A; Boriani G; Marchesini B; Strocchi E; Tomasi L; Balducelli M; Frabetti L; Ambrosioni E; Magnani B
    Cardiovasc Drugs Ther; 1990 Feb; 4(1):281-7. PubMed ID: 2285622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers.
    Hinderling PH; Tendolkar A; Dee CM; Barr WH; Seiberling M; Duerr H
    J Clin Pharmacol; 1995 Jul; 35(7):721-9. PubMed ID: 7560253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
    O'Hara GE; Philippon F; Gilbert M; Champagne J; Michaud V; Charbonneau L; Pruneau G; Hamelin BA; Geelen P; Turgeon J
    J Clin Pharmacol; 2012 Feb; 52(2):171-9. PubMed ID: 21508180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.
    Le Coz F; Funck-Brentano C; Morell T; Ghadanfar MM; Jaillon P
    Clin Pharmacol Ther; 1995 May; 57(5):533-42. PubMed ID: 7768076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.